IRS2 and breast carcinoma: IRS-2-expressing breast carcinoma cells are less invasive after treatment with an IGF-1R/IR small molecule inhibitor, which emphasizes the importance of upstream IGF-1R signaling through IRS-2 for the regulation of invasion [124].